Summary
The product NOLVADEX 10mg, manufactured by Unique Pharma, underwent independent testing to confirm its authenticity and potency. The sample, identified by batch number UN66437, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Tamoxifen Citrate, with a concentration of 9.85 mg, slightly below the labeled claim of 10 mg by 1.5%.
The testing process began on 27 February 2024, with the sample received on 07 March 2024, and analysis completed on 11 March 2024. While the results confirm relatively accurate dosing, it’s important to critically evaluate reseller-submitted samples to ensure reliability. Resellers may selectively submit high-quality batches, raising questions about product consistency across the market. Independent third-party testing remains vital for comprehensive validation. This report is intended as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: NOLVADEX 10mg
- Active Ingredient: Tamoxifen Citrate
- Batch Number: UN66437
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #39588
- Testing Ordered: 27 February 2024
- Sample Received: 07 March 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 9.85 mg
- Accuracy: 98.5% (-1.5% below label claim)
- Variance: -1.5
Verification Details
- Verification URL: https://janoshik.com/tests/39588_3Q114SWX98EN
Evaluation of Reseller-Submitted Testing
This analysis confirms the relative accuracy of the tested product but warrants scrutiny due to its submission and funding by the reseller Opitropin.EU. Resellers may selectively choose optimal batches for testing, which might not reflect overall market consistency. While Janoshik Analytical is recognized for its transparency and rigorous protocols, additional third-party testing across multiple batches would help validate the findings comprehensively.
Conclusion
The analysis indicates that NOLVADEX 10mg by Unique Pharma is slightly underdosed, with a measured concentration of 9.85 mg, reflecting relatively strong quality control for this batch. However, further testing across different batches is crucial for consistent assurance. This report aims to support educational and harm reduction efforts, assisting consumers in making informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce biases; however, it still provides valuable insights when critically evaluated alongside independent third-party results. Readers are encouraged to use this information responsibly.
